(Adds Outlook)
Amneal Pharmaceuticals, Inc. (AMRX) has raised its annual revenue outlook to a range of $2.70 billion to $2.80 billion from $2.55 billion to $2.65 billion expected earlier.
Excluding items, full-year profit per share is now projected to be $0.57 to $0.63, compared with the prior outlook of $0.53 to $0.63.
Analysts, on average, forecast the firm to post adjusted income per share of $0.61, on revenue of $2.65 billion, for the year.
Chirag and Chintu Patel, Co-CEOs of Amneal, said: "We are pleased to raise full year 2024 guidance driven by broad-based growth across our business. Coupled with this week's approval of CREXONT for Parkinson's disease, Amneal is well positioned to continue delivering durable long-term growth."
Q2 Results:
Amneal Pharmaceuticals, Inc. (AMRX) released a profit for second quarter that decreased from last year but beat the Street estimates.
The company's bottom line totaled $5.994 million, or $0.02 per share. This compares with $11.917 million, or $0.08 per share, in last year's second quarter.
Excluding items, Amneal Pharmaceuticals, Inc. reported adjusted earnings of $51.430 million or $0.16 per share for the period.
Analysts on average had expected the company to earn $0.14 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 17.1% to $701.780 million from $599.046 million last year.
Amneal Pharmaceuticals, Inc. earnings at a glance (GAAP) :
-Earnings (Q2): $5.994 Mln. vs. $11.917 Mln. last year.-EPS (Q2): $0.02 vs. $0.08 last year.-Revenue (Q2): $701.780 Mln vs. $599.046 Mln last year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.